Literature DB >> 17582072

Natalizumab for multiple sclerosis.

Richard M Ransohoff1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17582072     DOI： 10.1056/NEJMct071462

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  94 in total

1.  Innovative monoclonal antibody therapies in multiple sclerosis.

Authors:  Ralf A Linker; Bernd C Kieseier
Journal:  Ther Adv Neurol Disord       Date:  2008-07       Impact factor: 6.570

2.  CXCL12-induced monocyte-endothelial interactions promote lymphocyte transmigration across an in vitro blood-brain barrier.

Authors:  Shumei Man; Barbara Tucky; Anne Cotleur; Judith Drazba; Yukio Takeshita; Richard M Ransohoff
Journal:  Sci Transl Med       Date:  2012-02-01       Impact factor: 17.956

Review 3.  Immune modulating peptides for the treatment and suppression of multiple sclerosis.

Authors:  Ahmed H Badawi; Teruna J Siahaan
Journal:  Clin Immunol       Date:  2012-06-05       Impact factor: 3.969

Review 4.  Factors controlling permeability of the blood-brain barrier.

Authors:  Mohammed M A Almutairi; Chen Gong; Yuexian G Xu; Yanzhong Chang; Honglian Shi
Journal:  Cell Mol Life Sci       Date:  2015-09-24       Impact factor: 9.261

Review 5.  Recombinant T cell receptor ligands: immunomodulatory, neuroprotective and neuroregenerative effects suggest application as therapy for multiple sclerosis.

Authors:  Halina Offner; Sushmita Sinha; Chunhe Wang; Gregory G Burrows; Arthur A Vandenbark
Journal:  Rev Neurosci       Date:  2008       Impact factor: 4.353

6.  Immunology: Barrier to electrical storms.

Authors:  Richard M Ransohoff
Journal:  Nature       Date:  2009-01-08       Impact factor: 49.962

7.  Beta1 integrins differentially control extravasation of inflammatory cell subsets into the CNS during autoimmunity.

Authors:  Martina Bauer; Cord Brakebusch; Caroline Coisne; Michael Sixt; Hartmut Wekerle; Britta Engelhardt; Reinhard Fässler
Journal:  Proc Natl Acad Sci U S A       Date:  2009-01-28       Impact factor: 11.205

8.  Progressive multifocal leukoencephalopathy associated with brentuximab vedotin therapy: a report of 5 cases from the Southern Network on Adverse Reactions (SONAR) project.

Authors:  Kenneth R Carson; Scott D Newsome; Ellen J Kim; Nina D Wagner-Johnston; Gloria von Geldern; Craig H Moskowitz; Alison J Moskowitz; Alain H Rook; Pankaj Jalan; Alison W Loren; Daniel Landsburg; Thomas Coyne; Donald Tsai; Dennis W Raisch; LeAnn B Norris; P Brandon Bookstaver; Oliver Sartor; Charles L Bennett
Journal:  Cancer       Date:  2014-04-25       Impact factor: 6.860

Review 9.  Targeting cells in motion: migrating toward improved therapies.

Authors:  Jason W Griffith; Andrew D Luster
Journal:  Eur J Immunol       Date:  2013-05-13       Impact factor: 5.532

10.  JCV detection in multiple sclerosis patients treated with natalizumab.

Authors:  Saud A Sadiq; Lauren M Puccio; Edward W A Brydon
Journal:  J Neurol       Date:  2010-01-07       Impact factor: 4.849
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.